No change in ST segment during instillation of eyedrops of ophthalmic surgery: a study in elderly patients with heart disease (is present software/technology sufficiently sensitive)?
OBJECTIVE
To study the safety of instillation of eyedrops prior to ophthalmic surgery, which may potentially affect myocardial function, using continuous ST segment recording.


METHODS
Prospective study.


METHODS
Ambulatory surgery preoperative area at a university hospital.


METHODS
30 nonpremedicated ASA status III adults (aged 73 to 92 years) scheduled for cataract surgery with monitored anesthesia care (MAC).


METHODS
All patients were given ophthalmic drugs consisting of phenylephrine 2.5%, flubiprofen 0.03%, mydriacyl 1%, and cyclopentolate 1%.


RESULTS
ST segments were continuously monitored after the instillation of the eyedrops for a period of up to 15 minutes. A change of 2 mm or more in ST segments from baseline was considered significant. Results showed no significant change in ST segment. No patient reported any new cardiac symptoms or showed any evidence of dysrhythmias or hemodynamic changes.


CONCLUSIONS
The lack of significant finding most likely reflects the safety of these ophthalmic drops in their present dilute concentration, but it is also possible that the software and/or monitors used were not sensitive enough in their current configuration to detect possible subtle changes. Based on the results of this study, we conclude that the preoperative ophthalmic drugs used in our institution do not seem to have any adverse cardiovascular effects in this elderly patient population who are about to undergo cataract surgery with MAC.
Botz
G H
GH
Department of Anesthesiology, Duke University Medical Center, Durham, NC, USA.
Miser
J
J
Hoopes
S
S
Zweig
S
S
Brock-Utne
J G
JG
D000368:Aged; D000369:Aged, 80 and over; D000556:Ambulatory Surgical Procedures; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000209:etiology; D002387:Cataract Extraction; D003519:Cyclopentolate / Q000627:therapeutic use; D004562:Electrocardiography / Q000187:drug effects*; D005260:Female; D005480:Flurbiprofen / Q000627:therapeutic use; D006321:Heart / Q000187:drug effects; D006331:Heart Diseases / Q000150:complications*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D013677:Medical Laboratory Science / Q000295:instrumentation; D016343:Monitoring, Intraoperative / Q000295:instrumentation; D009184:Mydriatics / Q000627:therapeutic use*; D009883:Ophthalmic Solutions / Q000627:therapeutic use*; D010656:Phenylephrine / Q000627:therapeutic use; D011446:Prospective Studies; D012449:Safety; D012984:Software; D014331:Tropicamide / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D009184:Mydriatics; D009883:Ophthalmic Solutions; D010656:Phenylephrine; D005480:Flurbiprofen; D003519:Cyclopentolate; D014331:Tropicamide